logo
Plus   Neg
Share
Email

Dr. Reddy's Laboratories Enters Licensing Deal With Gilead Sciences For Remdesivir

Dr. Reddy's Laboratories Ltd. (RDY) announced that it has entered licensing deal with Gilead Sciences, Inc. (GILD) to register, manufacture and sell Gilead's antiviral drug Remdesivir for the treatment of COVID-19, in 127 countries including India.

Under non-exclusive licensing agreement, Dr. Reddy's will receive technology transfer from Gilead for manufacturing of Remdesivir. Dr. Reddy's would need to do manufacturing scale up and obtain regulatory approval for marketing of Remdesivir in respective countries.

In May, FDA has issued emergency use authorization for Gilead Science Inc's (GILD) antiviral drug Remdesivir to treat Covid-19.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Former Google engineer Anthony Levandowski was sentenced by a U.S. judge to eighteen months in prison for stealing trade secrets from Google's self-driving car unit before he defected to Uber's rival unit. Levandowski admitted that from 2009 to 2016, he worked in Google's self-driving car program, known then as Project Chauffer. JetBlue has strengthened its face covering policy, by prohibiting face masks with vents or exhalation valves, starting August 10. It will also no longer allow customers to claim exemptions from wearing a face covering altogether. Home Depot, Inc. is set to open three new distribution centers in Georgia over the next 18 months, which is expected to create an additional 1,000 new jobs in Greater Atlanta, including full-time and part-time positions. The home improvement retailer has already created more than 5,000 new jobs in Georgia over the last five years.
Follow RTT